SILO - Psyched: DEA's Denial Overruled Fed Psychedelics Change Psilocybin For Depression States Reform & More | Benzinga
DEA Psilocybin Rescheduling Denial Overruled By Federal Appeals Court
The U.S. Court of Appeals for the Ninth Circuit ruled against the Drug Enforcement Administration (DEA) in a psilocybin rescheduling lawsuit. Washington State physician Dr. Sunil Aggarwal filed the petition to secure psilocybin access for terminally ill cancer patients.
Aggarwal, who has been striving for legal psilocybin since 2020, initially sought approvals under right-to-try laws. His journey experienced a setback when the DEA rejected his request, leading him to pursue a formal rescheduling petition. The DEA's denial came in September 2022, citing the absence of FDA-confirmed "accepted medical use" for psilocybin. Keep reading HERE.
Interestingly, the federal agency has separately acknowledged psychedelics and cannabis research needs, and has suggested a revised, augmented production quota for several compounds. See updated amounts HERE.
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
Psychedelics company Cybin Inc. (NYSE: CYBN) shared its Phase 2 study interim results for its psilocybin analog CYB003 on Major Depressive Disorder (MDD) paired with the company’s EMBARK psychotherapy.
Psychedelics Reform In California, Wisconsin, Illinois, Massachusetts & Pennsylvania
Following our previous roundup, numerous states are moving the discussion around psychedelics reform whether through decriminalization, legalization or rescheduling proposals or ancillary measures to access to the new therapies.
A quick recap by November 3 includes California’s three ...